Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
10.80
0.00 (0.00%)
At close: Nov 14, 2025, 4:00 PM EST
10.79
-0.01 (-0.09%)
After-hours: Nov 14, 2025, 8:00 PM EST
Palatin Technologies Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
6.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | 4.49M | -363.59K | -7.49% |
| Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
| Jun 30, 2022 | 1.47M | 1.66M | -878.62% |
| Jun 30, 2021 | -188.60K | -306.59K | -259.84% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PTN News
- 2 days ago - Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 3 days ago - Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option - PRNewsWire
- 9 days ago - Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity - PRNewsWire
- 9 days ago - Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering - PRNewsWire
- 7 weeks ago - Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim - PRNewsWire
- 3 months ago - Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases - GlobeNewsWire
- 3 months ago - Palatin Announces 1-for-50 Reverse Stock Split - PRNewsWire